OSI to Market Serono’s Novantrone® for Oncology Indications
By Business Review Editor
Pharma Deals Review: Vol 2003 Issue 35 (Table of Contents)
Published: 3 Apr-2003
DOI: 10.3833/pdr.v2003.i35.923 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
OSI and Serono entered into an agreement to market Serono’s Novantrone® useful in the treatment of oncology indications, multiple sclerosis, acute nonlymphocytic leukemia and pain associated with advanced hormone-refractory prostate cancer...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS